期刊文献+

达比加群酯中空微球的制备及溶剂选择

Preparation of Hollow Microspheres for Dabigatran Etexilate and Solvent Selection
下载PDF
导出
摘要 目的改变制备中空微球中所需有机溶剂的不同配比,探讨有机溶剂对中空微球形成的影响。方法采用以乙醇与二氯甲烷之比为1∶1的最优配比制备达比加群酯中空微球,并测定其含量、体外释放度。结果制备的达比加群酯中空微球具有明显空腔,体外漂浮性能良好,体外释放行为符合Higuchi方程,2 h和12 h时累积释放率分别为45.3%和61.4%。结论所制备的达比加群酯中空微球具有缓释效果,有利于减少给药次数。 Objective To investigate the influence of organic solvent on the hollow microspheres formation by changing different propor-tions of organic solvent required in the preparation of hollow microspheres. Methods Dabigatran etexilate hollow microspheres were pre-pared by adopting the optimal proportion of 1:1 for dichloromethane and ethanol. Its content and in vitro release were calculated. Results The prepared Dabigatran etexilate hollow microspheres had obvious cavities,good in vitro floating performance,and the in vitro release behavior conformed to the Higuchi equation,the 2 h and 12 h cumulative release rates were 45. 3% and 61. 4% respectively. Conclusion The prepared Dabigatran etexilate hollow microspheres have a sustained-release effect and help to reduce the frequency of administration.
出处 《中国药业》 CAS 2014年第22期60-62,共3页 China Pharmaceuticals
基金 江苏省卫生厅职业技术教育研究课题 项目编号:J201206 2014年度江苏省教育厅高校"青蓝工程"资助项目
关键词 中空微球 达比加群酯 制备 体外释放度 hollow microspheres Dabigatran etexilate preparation in vitro release
  • 相关文献

参考文献13

  • 1Bishoy F. A new anticoagulant for a new era : review of recent data on dabiga- tran etexilate[ J ]. Clin Adv Hematol Onco1,2010,8(10) :679 - 702.
  • 2Kawashima Y, Niwa T, Takeuchi H, et al. Preparation of multiple unit hol- low microspheres (microballoons) with acrylic resin containing tranilast and their drug release characteristics (in vitro) anti floating behavior (in vivo) [ J]. J Control Release, 1991,16 : 279 - 289.
  • 3张向荣,朱悦铭,王晶,孙运栋,李三鸣,潘卫三.乳化-溶剂扩散法制备克拉霉素缓释微球[J].中国药业,2009,18(2):39-40. 被引量:3
  • 4Kumaresh S. Soppimath, Anandrao I/K, et al. Dewlopmen! of Hollow Mi- crospheres as Floating Controlled- Release Systems for Cardiovascular Drugs:Preparation and Release Characteristics[J]. Drug Dev lnd Pharm, 2001,27(6) :507 - 515.
  • 5Stangier J, Rathgen K, Stahleh, et al. The pharmacokinetics, pharmacody- namics and Iolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects [ J ]. Br J Clin Pharmacol, 2007,64 (3) : 292 - 303.
  • 6Yasunori S, Yoshiaki K, Hirotumi T, et al. Physicoehemieal properties to determine the buoyancy of hollow microspheres (mieroballoons) prepared by the emulsion solvent diffusion method [J]. Eur J Pharm and Biopharm, 2003,55 (2) :297 - 304.
  • 7蒋红艳,杨元娟,杨宗发,陈立书,江尚飞,张继芬.微球给药系统及其质量评价[J].中国药业,2012,21(13):1-2. 被引量:3
  • 8Sehulman S, Kearon C, Kakkar AK, el al. Dabigatran venus warfarin in the treatment of acute venous thromboembolism[J]. N Engl J Med, 2009,361 (5): 2 342 - 2 352.
  • 9肖宜超,刘启明.新型口服抗凝药达比加群酯研究进展[J].心血管病学进展,2011,32(4):575-578. 被引量:14
  • 10邢松松,王晓蕾,周付刚,苏信杰,杜玉民.达比加群酯的合成[J].中国医药工业杂志,2010,41(5):321-325. 被引量:18

二级参考文献82

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部